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In the marine environment there is a great potential for discovering new commercial drugs, 
and marine bioprospecting has previously led to the discovery of drugs available for clinical 
use, like Yondelis ® and cytosine arabinoside. In this work two hydroids were tested for 
anticancer and antibacterial activity. 
The organic extracts from the two hydroids, Halecium muricatum (M11046) and Halecium 




 screening against the human melanoma 
cell line and Streptococcus group B. This resulted in dereplication and isolation of eight 
possible bioactive compounds. After the isolation, the two purest compounds were analyzed 




C- NMR, HMBC combined with HSQC NMR and MS- MS for 
structure elucidation. From the structure elucidation it was obvious that the two compounds 
were phosphocholines, however the exact structures were not confirmed. These two 
compounds were tested against human melanoma, normal lung fibroblasts, breast cancer and 
prostate cancer for confirmation of bioactivity. Compound 1 showed a weak effect against the 
normal lung fibroblast cell line at 100 µg/ mL. The lack of activity against the human 





 screening against this cell line, or that it was a synergic effect responsible for the observed 
bioactivity. Compound 2 showed a weak effect against human breast carcinoma and were 
active against normal lung fibroblasts and human melanoma at 100 µg/ mL. Activity against 
normal lung fibroblasts was undesirable since this cell line was used as a toxicity control. 
Effect against this cell line indicates no specificity against cancer cell lines versus normal 
cells. This work is to the best of our knowledge the first work to test the anticancer and 
antibacterial effects of hydroids.  Another contribution of this work was the ability to detect 
phosphocholines present in a sample at an earlier stage. In bioprospecting the early detection 
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1.1 History of natural products  
 
For many millennia nature has provided humankind with treatments for different ailments and 
diseases. Plants have often been the remedy for these sufferings, which is evident from the 
“Ebers Papyrus”. This record dates back to 1500 BC, and is perhaps the best known record of 
ancient Egyptian medicine. The “Ebers Papyrus” documents over 700 drugs, and many of 
these drugs have a plant origin [1]. The Egyptians were not alone in practicing medicine in 
this era. There have been found records from Mesopotamia, which dates back to 2600 BC and 
records from China, which dates back to 1100 BC. The records from Mesopotamia documents 
use of about 1000 substances of plant origin [1]. What’s fascinating about these records is that 
we still use many of these substances today thousands of years after their discovery. Even 
today a major part of the world’s population, approximately 60%, relies on plants for 
medication [2]. Since plants had an indisputable role in curing various ailments, the search for 
new drugs started with plants, animals and microbes. The first commercial pure product was 
first sold in 1826 by E. Merck, and was morphine from the opium poppy Papaver somniferum 
[3]. Some of the major discoveries after morphine are the cardiac glycosides, digitoxin and 
digoxin, from foxglove (Digitalis purpurea) which are used against chronic heart failure [4]. 
The venom of the pit viper (Bothrops jararaca) led to the discovery of angiotensin converting 
enzyme inhibitors against various cardiovascular diseases like hypertension [4]. The ACE 
inhibitors are perhaps the most important class of antihypertensive drugs today. Another 
example of a compound found in nature with major impact on treatment of diseases is of 
course Alexander Fleming’s discovery of penicillin from the fungus Penicillum [4].  
The common ground for these discoveries, are that all have terrestrial origin. At this point in 
history, the marine environment was completely left out.  
 
1.2 Marine bioprospecting 
 
Bioprospecting or biodiversity prospecting is defined as the  
“process of collecting or surveying of a large set of flora (or fauna) for purpose of biological 




The start of marine biodiscovery begins with Bergmanns discoveries and identification of the 
spongothymidine and spongouridine from the Caribbean sponge Thetya crypta in the early 
1950s. These discoveries led to the identification of cytosine arabinoside, a compound used 
against leukemia [5].  
How marine organisms defend themselves against predators, competition against other marine 
organisms and diseases were questions which arose. This led to the discovery that especially 
sedentary, soft- bodied marine organisms use secondary metabolites as a defensive 
mechanism [5]. These secondary metabolites display characteristics of effective drugs, these 
traits are high potency, highly targeted mechanism of action, and the ability to permeate 
membranes, since the metabolites need to be intracellular to be effective [5].  
Other reasons pro marine bioprospecting is the high biodiversity in the marine environment 
and that the marine environment still is underexplored. Tropical and subtropical regions are 
the regions that have been explored in the largest scale, while the Arctic regions are virtually 
unexplored [1].  David Newman said in his lecture in Tromsø in March 2012, “the coral reef 
is the rainforest of the ocean”. This implies the vast biodiversity in the marine environment, 
and in nature. Newman also said that “Mother nature doesn’t make a structure unless it has a 
function. We just don’t know what it does yet”. This is obvious, since production of 
metabolites from an organism is energy consuming. If the organism made unnecessary 
molecules or metabolites, that organism would face extinction. Because of the biodiversity 
and the purpose behind every metabolite, the marine environment, and nature in general, is a 
perfect place to look for new drugs. 
From statistics it is evident that a major part of new small molecule drugs come from nature, 
as much as approximately 50% in the years 2000 to 2010, while combinatorial chemistry has 
failed in the search for new drugs, or new chemical entities. Only one “de novo” new 
chemical entity was discovered between 1981 and 2010. However, the role of combinatorial 
chemistry in chemical altering of new scaffolds found in nature is undisputable, since the new 
chemical entities become more potent and gains greater activity [6].  
Marine bioprospecting is a promising field because extracts from marine organisms are more 
likely to lead to anticancer drugs than extracts of terrestrial origin, and because there still 







1.3 Sources of marine natural products 
 
In the early stages of marine bioprospecting before the scuba technique was available, the 
collection of samples were limited to intertidal areas. Some of the first creatures to be 
analyzed were red algae, sponges and soft corals. With the advent of the scuba technique, the 
diversity of creatures available for analyzing increased compared to the creatures previously 
available. Creatures now available for examination were marine cyanobacteria, marine fungi 
and marine eubacteria, which led to the realization that many compounds isolated from 
macroorganisms like sponges actually were secondary metabolites produced by microbes. 
This discovery inspired groups to cultivate marine bacteria, which gave a reliable supply of 
samples to analyze. However, it is estimated that today still only 1 % of bacteria from 
seawater have been cultured. This cultivation has obviously given results, since the majority 
of marine natural products which are FDA approved or in phase I- III trials originate from 
bacteria [8]. Sponges have for a long time been the marine invertebrate which researchers 
were most interested in, however lately Cnidarians have started to attract attention because of 
their production of venoms and toxins [7].  
 
Halecium muricatum and Halecium beanii 
 
The organisms analyzed in this work are Halecium muricatum (M11046) and Halecium 
beanii (M11047). They are closely related species, belonging to the same genus namely the 
class Hydrozoa (Phylum Cnidaria). Hydroids are small, abundant colonial species. In the 
hydroid colonies, each individual is called a polyp, which buds out from a main stem. This 
stalk is fastened to the substrate, often on algae, a rock or a shell. The polyps are 
interconnected through the stem and the whole colony shares a common gastrovascular 
cavity. One character trait shared by many colonial animals, including hydroids, is that the 
individuals exhibit morphological polymorphism. This means that the colony possesses two 
or more structurally and functionally different kinds of individuals. Two common kinds of 
individuals are the gastrozooids, which captures food and take part in digestion, and the 
gonozooids which plays a vital role in asexual reproduction. Medusae are budded from the 
gonozooids. They represent the sexually reproducing generation of the hydroid colony. 
Defensive individuals are common as well. The Halecium species are thecate hydroids, which 
mean they have hydrothecae. A hydrotheca looks like a goblet, which protects the individuals 
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in the colony. The hydrothecae in this family only envelop the lower part of the polyps, and 
can often take a stacked form.  Halecium species are separated by the form of their 
gonothecae, which are the reproduction polyps. If these polyps are not present, the 
identification of species is extremely difficult [9].  
 
 






















Cancer is a collective term for approximately 200 distinct types of diseases [10]. There are six 
hallmarks, or six alternations that lead to malignant growth. These hallmarks are self- 
sufficiency in growth signals, insensitivity to antigrowth signals, evasion of apoptosis, 
limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis [11].  In 
the year 2009, 27 520 persons got the diagnosis in Norway. Among women the most frequent 
type of cancer is breast cancer, and there were reported 2745 new cases in 2009 [10]. In a 
worldwide perspective, breast cancer is the leading cause of cancer death among women, as 
well as the most frequent diagnosed cancer [12].  The five year mortality is approximately 20 
%, but collectively one out of three will die because of breast cancer [13]. Among males 
prostate cancer is most common, and in the year 2009, 4299 men got the diagnosis in Norway 
[10]. The mortality is approximately 3 % [14]. Malignant melanoma is in Norway the second 
most frequent diagnosed type of cancer in the age group 15- 54 years. In 2009 there were 
1413 new cases diagnosed in Norway, and this incidence rate is one of the highest in the 
world [15] .The current forms of treatments for cancer are surgery, radiation and 
chemotherapy. Even though the incidence of breast cancer in all ages in Norway is increasing, 
the mortality rate for breast cancer is declining [16]. The reason for this decline in mortality 
may be the result of a better national screening program and more effective treatment. Yet 
today’s treatment with cytostatics is still associated with many serious side effects. Some 
side- effects are constipation, diarrhea, nausea, vomiting, anemia, neutropenia and 
thrombocytopenia [17]. With radiation therapy one of many side- effect is second malignant 
neoplasms [18]. Obviously there is a need for more target specific and effective treatments. 
For some types of cancer the treatment is not good enough, which is the case for lung cancer. 
The five year survival rate after diagnosis is lower than 20 % [19].  
A recently approved cancer drug in EU was Trabectidin (Yondelis ®) from the marine 
tunicate Ecteinascidia turbinate. Trabectidin function as a DNA alkylating agent, which 
challenge the DNA repair machinery. In EU Trabectidin’s approval was as a second- line 
treatment for advanced soft tissue sarcoma. Paclitaxel (Taxol ®) from the bark of Taxus 
brevifolia, Pacific yew, dominates the cytotoxic marked [20] with its clinical use against 
ovarian cancer, breast cancer, non-small-cell lung cancer, small cell lung cancer and cancers 
in the head and neck [21]. However, because of resistance induced by efflux proteins and 






A new era in the treatment of infectious diseases started with Alexander Flemings discovery 
of penicillin from the fungus Penicillum notatum in 1928 [22]. Penicillin was not utilized as 
an antibiotic until the 1940s, when scientists from England and USA developed the 
appropriate fermentation technology to yield high- purity penicillin in large enough quantities. 
After the discovery of the fermentation technique, and during the following decade, there was 
an enormous focus on antibiotic research, which led to the discovery of the better part of 
antibiotic classes that we currently use therapeutically [23]. In the 1960s and early 1970s, it 
was thought that the previous problematic infectious diseases were overcome [24]. However, 
the situation today is that only four new classes of antibiotics have arrived at the marked since 
the early 1960s [25], and the occurrence of multidrug- resistant bacteria has led to infections 
which have few, or none treatment options [24]. To handle the critical situation with 
multidrug- resistant bacteria, new classes of antibiotics needs to be developed. Only new 
classes of antibiotics with novel mechanisms of action can handle drug resistance [24]. In 
spite the fact that there is a need for new classes of antibiotics which show novel mechanisms 
of action, the research and development for antimicrobials are reduced or ceased by many 
pharmaceutical companies [26]. The reasons why pharmaceutical companies reduce or cease 
their R&D funding may be the fact that developing a new drug is a costly and lengthy 
process. The development of a new drug takes 8-15 years, and may cost 800 million USD 
[27]. Another reason may be that developing a new drug against an infection is less 
economically attractive [24]. The treatment of an infection is short term, and pharmaceutical 
companies focus now largely on chronic diseases prevalent among the elderly, for instance 
hypercholesterolemia and hypertension which is economically attractive.  The new antibiotics 
marketed in the past years are only new generations of already existing classes of antibiotics, 
which are synthetic tailored and only results in marginally improved drugs [27]. Because of 
the lack of new antibiotics with novel mechanisms of action and the fact that infectious 
diseases cause 17 million deaths annually worldwide [26], the importance of research centers 





1.6 MabCent- Centre for Research based Innovation (CRI) 
 
MabCent- CRI was established by the Research Council of Norway in March 2007, and is a 
centre for research- based innovation. The main objective of MabCent- CRI is to find and 
develop high- value bioactive products through screening of Arctic or sub- Arctic organisms 
for innovative and commercial use. MabCent uses High- throughput screening (HTS) in its 
work to detect bioactivity in different bioactivity assays. HTS is an automated process which 
enable the screening of large numbers of compounds for bioactivity [4]. The screening 
method combines chromatographic bioassay- guided fractionation with various bioactivity 
assays, and is essential in the discovery of new drugs or bioactive products.  The organisms in 
focus are marine bacteria, algae and benthic invertebrates [28]. Marbank collect samples, 
determine the taxonomy of the samples, organize the samples and produces extracts for the 
high throughput screening platform Marbio. Active compounds are isolated and characterized 
by MabCent. Other groups at the Univeristy of Tromsø and the University Hospital in North 
Norway also determine mode of action of bioactive compounds. The therapeutic areas that 
MabCent focuses on are antibacterial activity, antitumor activity, anti- inflammatory activity, 
diabetes, obesity, antioxidants and immunostimulants. The obtaining of samples is done by 
surveys in marine waters from the coast of northern Norway to Svalbard. The methods used to 
obtain the samples are divers, dredging and trawling [29]. Previous discoveries made by the 
biotech industry in Tromsø, were not done by systematic approaches, and hopefully will the 











2.  Aim of this study 
 
The main goal of this work was to isolate and characterize the structure of bioactive 
compounds from the marine benthic organisms Halecium muricatum (M11046) and Halecium 
beanii (M11047). This was achieved by screening the extracts from the organisms against 
different cancer cell lines and bacterial strains, and to identify the structure of active 
compounds as well. Although the main priority was the anticancer screening, the bioactivity 
screening against different bacterial strains was carried out to detect if there was a general 





















The purpose of extraction was to extract as many compounds from the biomass sample as 
possible over in a solution. Aqueous and organic extraction was chosen to get a broad 
spectrum of compounds available for bioactivity testing. When the biological samples were 
collected in the Barents Sea by MabCent, the first part was to identify the species. The 
preparation of samples began with freeze drying of the biological sample, followed by 
pulverization of the freeze dried sample. This was done because the hydrophilic compounds 
can be stored in membrane pockets, be protected by lipophilic substances or be bound to 
membranes. Then the extraction of the pulverized and freeze- dried sample began. The 
solvents used in extraction were based on the characteristics of the desirable compounds we 
wanted to extract.  For the aqueous extraction water was used to extract the hydrophilic 
compounds in the material. The organic compounds, or the hydrophobic compounds, were 
extracted using dichloromethane and methanol. 
Before HPLC fractionation of the organic extract, liquid- liquid- extraction was done by using 
acetonitrile and hexane in a separating funnel. The acetonitrile phase is the phase where 
potential compounds may reside, and the hexane phase is the phase where the most lipophilic 
compounds reside. Drugs need to be sufficiently lipophilic to cross membranes, but should 
not be so lipophilic that they precipitate in the blood, which very well may be the case with 
compounds from the hexane phase. Drugs precipitating in the blood can have a fatal ending 
for the patient receiving the treatment. Therefore the highly lipophilic hexane phase was not 
used, while the acetonitrile phase was brought further in the process.  
 
3.2 High Performance Liquid Chromatography and Mass Spectrometry 
 
High Performance Liquid Chromatography (HPLC) is a chromatographic method used to 
separate compounds in a liquid. A HPLC setup consists typically of an injector, a column, a 
pump, mobile phases and a detector. The retention time is the time it takes for the compound 
to traverse the column, and can give an indication about the characteristics of the compound 
eluted. The main principle is that components in the sample are carried by the mobile phase 
through a column, and when the compounds have arrived at the end of the column they enter 
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a detector. The detector measures one or multiple characteristics of the analyte, depending on 
what kind of detector is used. This is converted to a signal which is displayed as a 
chromatogram, which shows the signal versus time. Ultra Performance Liquid 
Chromatography (UPLC) involves smaller particle sizes, lesser internal diameters of the 
column and a higher counter pressure, which results in a higher resolution of the analyses.  
The column and the mobile phase used in HPLC/ UPLC separate the sample compounds. The 
perhaps most widely used column is the reverse phase column. The stationary phase in the 
reverse phase column is non- polar, compared to what historically was named normal phase 
chromatography where the stationary phase was polar. The column is called reverse phase 
since the introduction of this column reversed the elution order [30].  In the reverse phase 
column the hydrophobic stationary phase is bound to the silanol groups, where most often the 
hydrophobic group is C 18. The mechanism of retention utilized in reverse phase columns is 
van der Waals forces, which retard hydrophobic molecules the most, and small hydrophilic 
molecules the least. The small hydrophilic molecules will then elute first, which obviously 
gives them the shortest retention time. Hydrophobic molecules will elute last, and have the 
longest retention time.  
Two commonly used detectors in a HPLC setup are the UV- detector and the mass 
spectrometry detector. In this work both detectors were used. With the mass spectrometry 
detector the compounds need to be ionized before they are detected. Within LC- MS 
electrospray ionization is a common ion source, where the compounds undergo a loss or gain 
of a proton, and the product is called a deprotonated or protonated molecular ion. Other 
possibilities are the formation of adducts, which is called a pseudo molecular ions.  In this 
work Ultra Performance Liquid Chromatography- Mass spectrometry with electrospray 
ionization (ESI) in positive mode was used with a time- of- flight mass spectrometer.  
 
3.3 Structure elucidation 
 
Ultra violet (UV) spectroscopy 
The value of utilizing UV- spectroscopy is to detect functional groups like ketones, esters and 
amides, as well as the presence or absence of unsaturated functional groups. The phenomenon 
that creates UV- peaks is the excitation of an electron from an orbital, which requires energy. 
This leads to an electron transition from a lower to a higher energy state [31].  UV- 
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spectroscopy is based on Beer’s law. Beer’s law states that if monochromatic electromagnetic 
radiation with the intensity I0 is directed towards a solution of an analyte, some of this 
radiation will be absorbed. The rest of the radiation will pass through the sample. The 
intensity of the radiation is measured on the back of the sample.  
A = log (I0/I) = a x b x c, 
Where A is the absorbance, a is absorbency, b is the path length and c is the concentration of 
the analyte [32]. 
UV- spectroscopy can be used for quantitative and qualitative measurements. Identification is 
performed by comparing the spectrum of an unknown analyte with a reference spectrum for a 
known compound. If the spectra are identic, it is highly probable that the analyte and the 
compound is the same. However multiple compounds can have nearly identical spectra, and 
other structure elucidation techniques are often required [32]. In this work UV spectroscopy 
was used as a general detector, not as a part of the structure elucidation. However as written 
earlier, UV spectroscopy can be used in structure elucidation. 
 
Nuclear magnetic resonance 
In the process of structure elucidation the obtaining of 
1
H- NMR and 
13
C- NMR is crucial. 
The sample in the NMR spectrometer is exposed to radiofrequency radiation in the presence 
of a strong external magnetic field. In 
1
H- NMR the spectrometer measures the energy levels 
of the nucleus of hydrogen, which is possible because the radiation in the presence of the 
magnetic field can change the orientations of protons in the nucleus [33]. The NMR spectra 
are generated by the magnetic properties of the atomic nuclei of the analyzed elements. These 
magnetic properties are generated by the spinning charge of electrons [34]. This gives 
information about the hydrogens in the molecule. The properties of the proton of hydrogen 
appear also in 
13
C.  The 
13
C- NMR spectroscopy is based on the presence of 
13
C in a mixture 
with 
12
C, since only 
13
C is detected in the analysis. These spectra are often simplified by 
decoupling the effects of the hydrogens, and reveal the different kinds of carbon atoms in the 
compound [33]. Other NMR methods used in this work was HSQC (Heteronuclear Single- 
Quatum Correlation ) and HMBC (Heteronuclear Multiple- bond Correlation). These spectra 
are often coupled together giving information about the correlation between two different 
nuclei separated by one bond (HSQC) where each unique proton coupled to a carbon gives a 
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peak, and correlations over longer ranges approximately 2-4 bonds (HMBC).  With COSY 
(COrrelation SpectroscopY) one can detect which atoms are connected to each other.  NMR is 
a non- destructive method of analysis.  
 
High resolution Mass spectrometry 
High resolution mass spectrometry is used to accurately determine the mass of the molecular 
ion in structure elucidation to identify or confirm the molecular formula for a compound. The 
spectrometers have evolved over time to overcome limitations of this technique like peak 
broadening and interfering ions. This evolution led to the more recent techniques like 
electrospray ionization (ESI), matrix- assisted laser desorption/ ionization (MALDI) and time- 
of- flight (TOF). In this work ESI and TOF was used [35].  
 
MS- MS 
In MS- MS, or tandem mass spectrometry, two mass analyzers are coupled in series. The first 
MS detects the mass of a selected ion (for example m/z 482) out of a mixture of ions created 
in the ion source of the first MS. Collision activated decomposition (CAD) occurs in an 
intermediate region, which leads to fragmentation of the selected ion. These fragments created 
by CAD are detected by the second MS. These fragment ions from the parent ions gives 
information about substructures and functional groups [36]. MS- MS instruments are often 














Table 1: List of chemicals used in this work. 
Chemical Manufacturer/ producer/Firm 
Acetonitrile (HPLC grade) Merck, Darmstadt, Germany 
Acetonitrile (UPLC grade) Merck 
Aqueous one cell solution Promega, USA 
Brain heart infusion Oxoid, Cambridge, England 
Dichloromethane Merck 
DMSO Sigma- Aldrich, St. Louis, MO, USA 
Dulbecco’s Phosphate Buffered Saline Biochrom, Berlin, Germany 
D- MEM Invitrogen, California, USA 
E- MEM Biochrom 
Ethanol 96 % Sigma- Aldrich 
Fetal bovine serum Biochrom 
Formic acid  Merck 
Gentamicin Biochrom 
Hexane Sigma- Aldrich 
Methanol  Sigma- Aldrich 
MilliQ Water Millipore, Billerica, MA, USA 
Müeller Hinton bullion Merck 
NEAA Biochrom  
RPMI- 1640 Biochrom 





Preparative HPLC- MS 
Waters 600 E (Milford, MA, USA) 
Waters 2996 photodiode array detector  
Waters 3100 mass detector 
Waters 2767 Sample manager 
Waters flow splitter 
Waters prep degasser 
Waters 515 HPLC pump 
Software: MassLynx V4.1 SCN714 
Column:  Aqueous extracts: Atlantis ® Prep dC18 10µm 10 x 250 mm 
  Organic extracts: Xterra ® Prep RP18 10 µm 10 x 300 mm  
  Purification: XSelect CSH Prep Fluoro- Phenyl 5µm 10x 250 mm  
Pre- column: XTerra ® Prep RP 18 10 µm 10 x 10 mm  
 
 
High Resolution- MS 
Waters Acquity UPLC 
Detector: Waters LCT Premier 
Software: MassLynx V4.1 SCN639 
Column: Acquity UPLC ® BEH C18 1.7 µm 2.1 * 50 mm 
 
NMR: 
Varian Spectrometer 600MHz (Varian, Palo Alto, USA) 
Probe: inverse detection HCN cryoprobe 
 
MS-MS 
Waters Xevo TQ MS 
Programvare: Masslynx 4.1 
Collision gas: Argon 4.0 (Aga, Oslo, Norway) 




Minishaker (VWR International, Radnor, Pennsylvania, USA) 
Rotary evaporator Heidolph Laborata 4002 (VWR International) 
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Edmund Bühler GmBH 5m- 30 control shaker (Hechingen, Germany) 
Centrifuges:  Heraeus Multifuge 3 S-R (Thermo Fisher Scientific, Waltham, MA, USA) 
  Heraeus Biofuge Pico (Thermo Fisher Scientific) 
Freeze- dryer: Heto Power Dry PL9000 (Thermo Fisher Scientific) 
IKA ® A11 basic grinder (IKA works, Staufen, Germany) 
SC250 Express SpeedVac Concentrator (Thermo Fisher Scientific) 
RTV 4104 Refrigerated Trap (Thermo Fisher Scientific) 
Victor 3 Multilabel Counter (PerkinElmer, Waltham, MA, USA) 
- Software: WorkOut 2.5 (dazdaq, Brighton, England) 
Heidolph Incubator 1000 (VWR International) 





























5.1 Retrieving the specimens, extraction and fractionation 
 
5.1.1 Retrieving the specimens 
 
The specimens of Halecium muricatum (M11046) and Halecium beanii (M11047) were 
collected with an Agassiz dredge trawl at 30 m depth northwest of 
Spitsbergen (74º19’N,19º8’E) in May 2009. Identification was performed by Robert Andre 
Johansen, Marbank and confirmed by Ninel Panteleeva, Institute for Marine biology in 
Murmansk. The biomass sample was stored in the dark at -22 °C until further used and 
a reference specimen was deposited as a sub-sample in the Norwegian National Marine 
Biobank (Marbank), University of Tromsø, Norway. 
 
5.1.2 Extraction of Halecium muricatum and Halecium beanii 
 
Pre- treatment of samples before extraction 
 
The purpose of the pre- treatment of samples was to prepare the sample for extraction. 
This method is appropriate for samples in the weight range of 100g – 500 grams. The frozen 
organism was stored in the freezer, and thawed in room temperature or in the refrigerator. The 
samples were dissected, transferred to glass flasks on an ice bath and frozen overnight at – 20 
°C. The next day the samples were cut into 1 cm dices, weighed and frozen. Afterwards the 
samples were freeze- dried for 2-3 days, and grinded. The grinded samples were weighed and 





The purpose of the extraction was to produce aqueous and organic extracts. The aqueous 




First ultra-pure water (Milli-Q water) was added to the samples. The amount added was 
approximately ten times of the dry weight of the pre- treated samples. Then the flasks were 
shaken by hand, and stored in the refrigerator at 5 °C. At the end of the day the samples were 
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shaken again, and stored overnight in the refrigerator. The next day the samples were 
distributed to two 0.7 L centrifuge flasks, and centrifuged for 30 minutes at 3400 g at 5 °C. 
The supernatant was removed and transferred to a flask. Then there was a second round of 
extraction, where 750 mL of Milli- Q water was added to the centrifuge flasks for Halecium 
muricatum, and 1200 mL for Halecium beanii. The samples were mixed with a spoon, and 
were stored for 30 minutes in the refrigerator at 4 °C. After the storage, the samples were 
centrifuged by the same conditions as the first extraction. After the second round of extraction 
each sample had two supernatants. The two supernatants were pooled, frozen at – 20 °C and 
freeze dried overnight. The two pellets from the two rounds of extraction were transferred to 





The pellet from the aqueous extraction was used to produce the organic extract. Extraction 
agent was added slowly, until the ratio extraction agent: sample (dry weight) was 10:1. For 
Halecium muricatum 800 mL of extraction agent was used, and for Halecium beanii 1400 mL 
was used. The extraction agent used was DCM and methanol, mixed to a 1:1 ratio (volume- 
volume). After the extraction agent was added, the sample was shaken and stored in the 
refrigerator at 5 °C. At the end of the day, the sample was shaken, and stored overnight in the 
refrigerator. The next day the sample was vacuum filtrated (Whatmann no. 3 filter). The 
extraction and vacuum filtration of the pellets was repeated, only with half of the amount of 
extraction agent that was used in the first round. Before the last vacuum filtration, the sample 
was stored in the refrigerator for 30 minutes with the extraction agent. The two filtrates were 
transferred to a flask (without the screw cap, because of the vapor pressure). Then the organic 
extract was concentrated by vacuum evaporation in the rotavapor at 40 °C in a water bath, 
until the sample was nearly dry. The organic extract was then transferred to a 13 mm test tube, 








5.1.3 HPLC fractionation of Halecium muricatum and Halecium beanii 
 
Preparation of the extracts from Halecium muricatum and Halecium beanii before 
HPCL fractionation 
 
Aqueous extract:  
 
The samples were weighed in polystyrene centrifuge tubes, approximately 200 mg from 
Halecium muricatum and Halecium beanii, and 2000 µL Milli-Q water was added to each 
tube. Afterwards the samples were shaken for 90 minutes at 100- 160 RPM. Then the samples 
were transferred to a new centrifuge tube, and frozen overnight. The next day the samples 
were thawed for 5- 10 minutes, mixed well and centrifuged at 3400 g for 30 minutes at 5°C. 
Afterwards the supernatants were transferred to 25 mL round flasks, and evaporated in the 
rotavapor to less than 1 mL at approximately 70 mbar pressure in a 40 °C water bath. Then 
the supernatants were filtrated through a 0.22 µm Millex GS filter in HPLC tubes. Afterwards 
the samples were mixed well with a pipette and the volumes were adjusted to 1000 µL with 




The samples were weighed in 13 mm glass test tubes, approximately 200 mg from Halecium 
muricatum and Halecium beanii, and dissolved in 3 mL hexane. Afterwards the samples were 
shaken with the mini shaker, 3 mL acetonitrile was added, and the samples were shaken in the 
mini shaker again. Then the samples were centrifuged at 20 g for 3 minutes. The hexane- 
phase (on top) was transferred to another test tube, and 3 mL acetonitrile was added. 
Afterwards the samples were shaken on the mini shaker, and centrifuged again. The two 
acetonitrile phases were transferred to 25 mL round flasks, and evaporated under low pressure 
with a gradual pressure reduction down to 150- 180 mbar. The evaporation was stopped when 
there was approximately 1 mL left in the flask. The volume of the samples was adjusted to 
1000 µL with 90 % acetonitrile and centrifuged at 16200 g for 30 minutes. Afterwards the 










HPLC fractionation of Halecium muricatum and Halecium beanii 
 
Mobile phases: 
A: 0.1 % formic acid in Milli- Q water 
B: 0.1 % formic acid in acetonitrile 
 
Make-up pump solution: 80 % aqueous MeOH w/ 0.2 % formic acid 
Wash solution 1: 5 % MeOH in Milli-Q water 
Wash solution 2: Acetonitrile (HPLC grade)  
 
Injection volume: 900 µL 
Injector: 1000 µL 
 
Column: 
Aqueous extract: Atlantis ® Prep T3 OBD 10µm 19x250 mm. 
Organic extract: XTerra® Prep MS C18 OBD 10 µm 19x250 mm. 
 
Conditions: 
Source temperature: 120 °C 
Desolvation temperature: 300 °C 
Desolvation gas flow: 500 L/ hour 
 
During the HPLC fractionation 99 % of the mobile phase flow goes to the collection of 
fractions, and 1 % goes to the UV- and MS- detectors. The flow directed to the detectors is 
very low compared to the flow to the fractionation, and would lead to a time lag between the 
detector signal and fractionation if left unattended. A make- up pump increases the flow to the 
detectors and eliminates this problem. The wash solutions wash the injector, and the first 
wash solution (weak wash) washes out water soluble compounds. The second wash solution 










Table 2: Gradient used for the fractionation of the aqueous extract: 
 
Time (min) Flow (mL/ min) % A % B 
Initial 6 95 5 
3 6 95 5 
30 6 50 50 
35 6 5 95 













Each extract was fractionated into 40 1 minute fractions, each fraction was 6 mL. The 
fractions were transferred to four identical deep well plates, with 1.33 mL from each fraction 
in each deep well plate. The deep well plates were dried in a SpeedVac to evaporate the 
acetonitrile and formic acid, and then freeze- dried to remove the water. 
Since the aqueous and organic extracts were not previously fractionated or purified a pre- 
column was used. 
 
Dissolution of HPLC fractions for bioactivity screening 
 
Growth inhibition and antitumor assay: 
 
There were two samples, M11046 and M11047, and each sample had an aqueous and organic 
extract. In total eight deep well plates were used in the growth inhibition and antitumor assay.  
First 7.5 µL of DMSO were added only to the deep well plates with organic fractions, 
followed by shaking of the samples for 2.5 hours. Then 750 µL of autoclaved Milli- Q water 
Time (min) Flow (mL/ min) % A % B 
Initial 6 80 20 
2 6 80 20 
30 6 0 100 
40 6 0 100 
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was added to the plates used in the growth inhibition assay. The same amount of RPMI- 1640 
was added to the plates in the antitumor assay, and the deep well plates were shaken for 30 
minutes. Afterwards 750 µL of autoclaved Milli- Q water was added again (RPMI- 1640 for 
antitumor assay), and the deep well plates were shaken for 3 minutes. DMSO was only added 
to the deep well plates with organic fractions to dissolve the fractions, since the organic 




5.2 Bioactivity testing 
 
5.2.1 Growth inhibition assay 
 




Table 4: Bacterial strains used in the growth inhibition assay. 
 
Bacterial strain 
Staphylococcus aureus ATCC 25923 
Escherichia coli ATCC 25922 
Enterococcus faecalis ATCC 29212 
Pseudomonas aeruginosa ATCC 27853 





The strains of bacteria (see table 4) were plated from freeze stock (- 80 °C) to blood agar 
plates overnight. Then the bacterial strains were sown out from blood agar plates to 8 mL 








Table 5: The appropriate growth medium, incubation time and bacterial density of the different strains of 
bacteria. 
 
Bacterial strain Growth medium Incubation time (h) Bacterial density 
S. aureus MH- broth 2,5  0,5 – 3 x 10
5
 CFU/ml 
E. coli MH- broth 1,5 0,5 – 3 x 10
5
 CFU/ml 
E. faecalis BHI – broth 1,5 0,5 – 3 x 10
5
 CFU/ml 
P. aeruginosa MH – broth 2,5 3 – 7 x 10
4
 CFU/ ml 







For exponential growth, 2 mL from the bacterial suspension from day one were transferred to 
25 mL fresh growth medium. Then the bacterial suspensions were incubated (see table 5 for 
appropriate incubation times). After the incubation, 100 µL of this bacterial “stock” 
suspension was added to a glass tube containing 9.9 mL of growth medium. The glass tube 
was shaken with the mini shaker, and 2 mL was transferred to a falcon tube containing 18 mL 
of growth medium. In total, the suspension of bacteria was diluted 1000 times. This dilution 
was done for each strain of bacteria. Then 50 µL of the HPLC fractions and 50 µL of the 
bacterial suspension were added to each well in a micro titer plate. Each bacterial strain had 
one micro titer plate, and each HPLC fraction was added in two parallels. The micro titer 















N 1 1 9 9 17 17 25 25 33 33 P 
N 2 2 10 10 18 18 26 26 34 34 P 
N 3 3 11 11 19 19 27 27 35 35 P 
N 4 4 12 12 20 20 28 28 36 36 P 
N 5 5 13 13 21 21 29 29 37 37 P 
N 6 6 14 14 22 22 30 30 38 38 P 
N 7 7 15 15 23 23 31 31 39 39 P 
N 8 8 16 16 24 24 32 32 40 40 P 
Figure 1: HPLC fraction setup in micro titer plates for growth inhibition assay. N = negative control, P = positive 
control, 1- 40 was the different HPLC fractions. 
 
Controls: 
- Negative control: 50 µL growth medium and 50 µL sterile distilled water. 
- Positive control: 50 µL sterile distilled water and 50 µL bacterial suspension. 
 
Day 2 – bacterial control counting: 
 
For control counting, 100 µL of the bacterial “stock” suspension was diluted 1 000 000 times 
in autoclaved 0.9 % NaCl Milli- Q water. Then 100 µL from the diluted suspension was 
seeded on two LB- plates for control counting the next day.  
 
Day 2 – MIC determination of gentamicin 
 
To control the validity of the assay, it is essential to determine the MIC- values of gentamicin 
against the bacterial strains used in the assay. Diluted gentamicin, 50 µL, was added in the 
following concentrations; 0.01 µg/mL, 0.03 µg/mL, 0.06 µg/mL, 0.12 µg/mL, 0.25 µg/mL, 
0.5 µg/mL, 1 µg/mL, 2 µg/mL, 4 µg/mL, 8 µg/mL and 16 µg/mL. The micro titer plate was 
incubated at 37 °C and 5 % CO2 overnight, and visually inspected the next day. 
 
 
Day 3: Reading of results 
 
The plates containing the HPLC fractions were visually inspected for inhibition of growth, 
and fractions with growth inhibition were noted. The plates were also inspected 
25 
 
photometrically by the Multilabel Counter VICTOR
3
TM. The Multilabel Counter measures 
light absorbance at 600 nm, and the absorbance for the HPLC fractions were compared with 
the positive and negative controls. The fractions are defined active, questionable and inactive 
with the following absorbance: 
o Active < 0,05 
o Questionable: 0,05- 0,09 
o Inactive: > 0,09 
The term questionable activity is just a cutoff value between the terms active and inactive. 
Fractions that show activity in this term show weak activity.   
The gentamicin control plate was visually inspected, and MIC values were noted and 
compared to the expected MIC values for gentamicin against these strains of bacteria. The 
bacterial colonies on the LB- plates were counted, to check the concentration of bacteria.  
 
 




The purpose of the 2
nd
 screening was to confirm antibacterial effect found in the 1
st
 screening 
by testing the active fractions from the 1
st
 screening. The active fractions were only tested 
against bacterial strains they showed growth inhibition against in the 1
st
 screening. The setup 
of this method was the same as the 1
st
 screening. The only difference was that the active 
fractions were tested undiluted, diluted 1:2 and diluted 1:4 in two parallels (see figure 2 
below). 
 
N A(U) A(1:2) A(1:4) E(U) E(1:2) E(1:4) I (U) I(1:2) I(1:4)  P 
N A(U) A(1:2) A(1:4) E(U) E(1:2) E(1:4) I (U) I(1:2) I(1:4)  P 
N B(U) B(1:2) B(1:4) F(U) F(1:2) F(1:4) J(U) J(1:2) J(1:4)  P 
N B(U) B(1:2) B(1:4) F(U) F(1:2) F(1:4) J(U) J(1:2) J(1:4)  P 
N C(U) C(1:2) C(1:4) G(U) G(1:2) G(1:4) K(U) K(1:2) K(1:4)  P 
N C(U) C(1:2) C(1:4) G(U) G(1:2) G(1:4) K(U) K(1:2) K(1:4)  P 
N D(U) D(1:2) D(1:4) H(U) H(1:2) H(1:4) L(U) L(1:2) L(1:4)  P 
N D(U) D(1:2) D(1:4) H(U) H(1:2) H(1:4) L(U) L(1:2) L(1:4)  P 
Figure 2: Setup for active HPLC fractions in the micro titer plate. A-L are active fractions and the dilution is 
in the parenthesis. N and P are positive and negative controls. 
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 Screening:  
Thawing of cells from nitrogen container 
 
The cells were stored in a liquid nitrogen container, and when needed for assays the cell lines 
were thawed and maintained at 37 °C in 5 % CO2. The cryo tube containing the cell line was 
directly transferred to preheated sterile Milli- Q water, for quick thawing. The tube containing 
the cells was sterilized with 70 % ethanol, and the cells were resuspended in the ampoule with 
a pipette. The cell suspension was transferred to a 50 mL centrifuge tube, and 10- 20 mL 
growth medium (see table 6) was added. The tube was centrifuged for 7 minutes at 200 g. 
After the centrifugation the medium was removed and replaced with new medium, and mixed 
well to dissolve the cell pellet. The cell suspension was transferred to a culture flask and 
incubated at 37 °C and 5 % CO2. After 1-2 days the medium was changed to fresh preheated 
medium. When the cell culture had established a cell monolayer they were split into a new 
culture flask as described below. 
 
 
Table 6: Cell line, origin and appropriate medium. 
 





Human melanoma D- MEM + 10 % FBS + 10 
µg/mL gentamicin 
MRC5 CCL- 171™ Normal lung fibroblasts E-MEM + 10 % FBS + 1 % 
NEAA 
MCF7 HTB- 22™ Human breast carcinoma E- MEM + 10 % FBS + 1 % 
NEAA 
DU145 Unknown Prostate cancer RPMI- 1640 + 10 % FBS 
 
Splitting and seeding of cell lines on plates 
The purpose of cell splitting was to maintain cell lines in culture, and the purpose of seeding 
cells into micro titer plates was for bioactivity assays. Splitting of cells was done 





The medium and chemicals were first preheated to 37 °C in an incubator. Then the cell 
culture flask was inspected in the microscope to determine the amount that needed to be 
transferred to the new cell culture flask, since the amount that was transferred depended on 
the cell density. Afterwards the growth medium was removed from the old cell culture flask, 
and 10 mL PBS was added to wash the cell monolayer. The cells were washed with PBS to 
remove serum that inactivates trypsin, and PBS was removed after approximately 1 minute. 
Trypsin 0.25 %, 5 mL, was added. It was important to tilt the flask so that the whole cell layer 
was covered. Trypsin was removed after approximately 15 seconds, and afterwards the flask 
was incubated for approximately 5 minutes at 37 °C, and the monolayer was inspected to see 
if the cells had loosened. The cells were resuspended in 10 mL growth medium. Then 15 mL 
growth medium was added to the new cell culture flask, and 0.5- 1 mL of the resuspended cell 
culture was added to the new cell culture flask. The amount of resuspended cell culture that 
needed to be added to the new cell culture flask depended on the cell density of the old cell 




To ensure an appropriate cell concentration in the wells of the microtiter plate, which was 2x 
10
4
 cells/ mL, Burkes’ counting chamber was used to count and calculate the appropriate cell 
concentration for further use. Then 100 µL of the new cell suspension with the appropriate 
cell concentration was added to each well in the microtiter plate, and incubated overnight at 
37 °C and 5 % CO2. The next day the medium in the microtiter plate wells was removed and 
50 µL fresh RPMI- 1640 medium was added. Afterwards 50 µL of the HPLC fractions was 
added to the microtiter plates (see figure 3) in three parallels. The microtiter plates were 










 1 1 1 8 8 8 15 15 15   
 2 2 2 9 9 9 16 16 16 N  
 3 3 3 10 10 10 17 17 17 N  
 4 4 4 11 11 11 18 18 18 N  
 5 5 5 12 12 12 19 19 19 N  
 6 6 6 13 13 13 20 20 20 N  
 7 7 7 14 14 14      
            
 
Figure 3: Setup of HPCL fractions in anticancer assay. N = negative control, which is only medium. 1- 20 = 
fraction 1-20 in three parallels. The grey areas indicate wells only containing medium. 
 
 
The positive control is an average value calculated from separate setups with Triton X- 100. 
The value of the positive control is 0.181446. This positive control was used to calculate the 
cell survival of each fraction, using the equation below. 
 
    ̅  
 ̅    ̅  
                         
 
Where X1 was the optical density of sample well 
 ̅   is the positive control  
 ̅  is the mean OD values of the negative control 
 
 
Aqueous One Solution cell proliferation assay of Halecium muricatum and Halecium 
beanii 
 
Aqueous one solution (AQOS) was preheated to 37 °C in an incubator, then 10 µL AQOS 
was added to each well. The plates were incubated for one hour at 37 °C and 5 % CO2. 
Absorbance was measured at 485 nm by the DTX 880 Multimode Detector.  Metabolic active 
cells reduced the tetrazolium salt from AQOS (yellow color) to a formazan product (dark 
blue). Number of viable, or surviving, cells was directly proportional to the amount of 
formazan product formed. The color concentration was read by a spectrophotometer.  
The fractions were defined as active, questionable or inactive with the following percentage 
of cell survival: 
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o Active: < 50 % 
o Questionable: 50- 60 % 
o Inactive: > 60 % 
 
 
Anticancer assay – 2
nd
 Screening of Halecium muricatum and Halecium beanii 
 
Active fractions from the 1
st
 screening were tested in the 2
nd
 screening. The 2
nd
 screening was 
carried out the same way as the 1
st
 screening, except that the active fractions were tested 
against the A2058 cell line undiluted, diluted 1:2 and diluted 1:5 in three parallels (see figure 
4 below) 
 
 A(U) A(U) A(U) A(1:2) A(1:2) A(1:2) A(1:5) A(1:5) A(1:5)   
 B(U) B(U) B(U) B(1:2) B(1:2) B(1:2) B(1:5) B(1:5) B(1:5) N  
 C(U) C(U) C(U) C(1:2) C(1:2) C(1:2) C(1:5) C(1:5) C(1:5) N  
 D(U) D(U) D(U) D(1:2) D(1:2) D(1:2) D(1:5) D(1:5) D(1:5) N  
 E(U) E(U) E(U) E(1:2) E(1:2) E(1:2) E(1:5) E(1:5) E(1:5) N  
 F(U) F(U) F(U) F(1:2) F(1:2) F(1:2) F(1:5) F(1:5) F(1:5) N  
 G(U) G(U) G(U) G(1:2) G(1:2) G(1:2) G(1:5) G(1:5) G(1:5) N  
            
 
Figure 4: Display of HPCL fractions in the 2
nd
 anticancer screening. A-G = different fractions, U = undiluted, 1:2 























A: H2O + 0.1 % FA 
B: ACN + 0.1 % FA 
Wash solutions: 
Weak wash solution: H2O + 10 % ACN. 
Strong wash solution: 50 % ACN + 50 % H2O. 
 
Table 7: Gradient used in the dereplication of Halecium beanii. 
Time (min) Flow (mL/ min) % A % B 
Initial 0.350 80 20 
3.5 0.350 0 100 
 
Standard conditions for TOF- MS with ESI+: 
Capillary: 2.6 kV 
Cone 35 V 
Source temperature: 120 °C 
Desolvation temperature: 300 °C 
Cone gas flow: 5L/ hour 
Desolvation gas flow: 550 L/ hour 
 
Dereplication is the identification and subsequent removal of known compounds from the 




 anticancer assays, 
compounds from Halecium beanii (M11047) were chosen for dereplication. Inactive and 
active fractions were analyzed using UPLC- TOF- MS with ESI in positive mode in order to 
find compounds that could be correlated to the observed bioactivity. The bioactive fractions 
should contain other compounds than inactive HPCL fractions. Alternatively the bioactive 
fractions should contain more of the bioactive compound, or compounds, than the fractions 
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that did not show bioactivity. The elemental composition was calculated by Masslynx from 
the accurate mass and isotope distribution of the selected compounds. This elemental 
composition was used to search the Dictionary of Marine Natural Products for known natural 
products. If it was an unknown compound, or a known compound which had not previously 
shown bioactivity, then that was an interesting discovery. If the compound was known, and it 
had activity in the assays performed, then the discovery was unimportant, and this step 
prevents further waste of time.  
 
5.4 Isolation of possible bioactive compounds from Halecium beanii 
 
After the dereplication, eight possible bioactive compounds were found which needed to be 
isolated. Before isolation on HPLC, more of the organic extract was needed. Preparation of 
samples for HPLC was done according to section 5.1.3 under organic extract. This was done 
twice to assure that enough of the sample was available to complete further bioactivity 
screening on the isolated compounds. The isolation of the eight different compounds was 
done on the preparative HPLC, with an optimized gradient. 
 
Mobile phases: 
A: 0.1 % formic acid in Milli- Q water 
B: 0.1 % formic acid in acetonitrile 
 
Make-up pump solution: 80 % MeOH w/ 0.2 % formic acid 
Wash solution 1: 5 % MeOH in Milli-Q water 
Wash solution 2: Acetonitrile (HPLC grade)  
 
Injection volume: 100- 410 µL 









Table 8: Optimized gradient used for isolation of dereplicated compounds.  
Time (min) Flow (mL/ min) % A % B 
Initial 6 70 30 
2 6 70 30 
2.10 6 60 40 
20 6 50 50 
 
The MS- detector was programmed to trigger fraction collection by the protonated molecular 
weights [M+H]
+
 of the eight different compounds. After repeated HPLC injections the 
fractions were transferred to one flask for each compound. The compounds were then 
concentrated by evaporation under low pressure with a gradual pressure reduction.  
 
After the isolation the compounds were analyzed using UPLC- TOF- MS, with ESI in 
positive mode, to determine the purest compounds for further bioactivity testing. The mobile 
phases and wash solutions were the same as in section 5.3. 
Afterwards the samples were transferred to a pre-weighed glass tube and were vacuum 
evaporated. This was performed to find the amount of each compound available for further 
bioactivity testing. 
 
Table 9: Gradient used for determining the purest of the compounds using UPLC- TOF- MS. 
Time (min) Flow (mL/min) % A % B 
Initial 0.35 90 10 









5.5 Identification of possible bioactive compounds from Halecium beanii 
 
NMR 
The compounds with protonated masses of 454.3 and 482.3 were dissolved in 500 µL 
deuterated MeOH. The NMR spectra were provided on a Varian Inova spectrometer operated 
at 599.934 MHz for 
1
H- NMR, and for 
13
C- NMR it was operating at 150.863 MHz. The 
probe that was used was a cryogenically cooled inverse detection HCN probe with an 
enhanced proton channel (2
nd





HSQC (Heteronuclear Single- Quatum Correlation), HMBC (Heteronuclear Multiple- bond 
Correlation), COSY (COrrelation SpectroscopY), were acquired with a resolution of 1440 x 
200 complex data points. All spectra were acquired at 298 K. 
 
Wet1D: 256 scans, sweepwidth: 16 ppm, complex datapoints: 16k 
Carbon: 20000  scans, sweepwidth: 240ppm, proton decoupling and noe enhancement 
gCOSY: 16 scans @ 200x1439 complex points 
gHSQCAD: 64 scans @ 200x1024 complex points 
gHMBCAD: 64 scans @ 256x1024 complex points 
 
MS- MS 
The two compounds with protonated masses of 454.3 and 482.3 were analyzed by MS- MS 
for further structure elucidation, and were directly infused to the mass spectrometer by a built- 
in syringe. Cone voltage was optimized to get the highest possible signal for the protonated 
molecular ion, and the collision energy was optimized during the infusion to get the best 
possible daughter specter. The cone and desolvation gas used was nitrogen, and the collision 
gas used was argon.  
 
5.6 Confirmation of bioactivity 
 
The protonated mass of the compounds chosen for further bioactivity testing were 454.3 and 
482.3. After the dereplication and isolation of the two potential active compounds, the 
bioactivity needed to be confirmed. This was done due to the possibility that the compounds 
chosen were not the active compounds that showed initial activity. Since the main focus in 
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this work was bioactivity against cancer cells, only the anticancer assay was performed. The 
setup for this test was done as described in section 5.2.2. The only difference was the 
concentration of the isolated compounds used and the number of cell lines, to examine the 
possibility that the isolated compounds show cell line specificity. The cell lines used in this 
assay were A2058, MRC5, MCF7 and DU145. For the concentration gradient setup for this 
assay see figure 5 below. 
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Figure 5: Setup for confirmation of bioactivity. A = 454,3, B = 482,3. Compound concentration in brackets. The 









Halecium muricatum (M11046) 
 
For Halecium muricatum the weight of the biomass sample collected was 927 grams. After 
the freeze- drying and grinding, the dry weight of the biomass sample was 194 grams. This 
dry biomass sample was used first in the extraction of the aqueous extract which yielded 34.5 
grams and gave a percentage yield of 17.8 %. 
The biomass sample used in the aqueous extraction was then dried before the organic 
extraction. The dry weight of the biomass sample used for organic extraction was 148.0 g, and 
the extraction yielded 4.5 grams, which gave a percentage yield of 3.0 %. 
 
 
Halecium beanii (M11047) 
 
For Halecium beanii the weight of the biomass collected was 1293 grams. After freeze- 
drying and grinding the dry weight was 258.2 grams. This dry biomass sample was used in 
the aqueous extraction which yielded 49.5 grams, with the percentage yield of 19.2 %. The 
biomass sample used in the aqueous extraction was dried, before used in the organic 
extraction. The dry weight of the biomass sample used for organic extraction was 193.9 g, and 




Before fractionation, preparation of the extracts from Halecium muricatum and Halecium 
beanii was performed (see section 5.1.3). For the preparation of the aqueous extract 200.7 mg 
from H. muricatum and 201.1 mg from H. beanii was used. For the organic extract 218.1 mg 
from H. muricatum and 209.5 mg from H. beanii was used. 
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In the fractionation of the aqueous exctracts the injection peaks eluted at 3.35 minutes for 
Halecium muricatum (see figure 6, section A) and at 3.68 minutes for Halecium beanii (see 
figure 7, section A) in the UV chromatograms. The injection peak often consists of different 
salts with nearly no retention time. In the UV- chromatogram of H. muricatum many 
compounds were detected during the first 11 minutes. For Halecium beanii nearly all 
compounds were detected during the first 15 minutes (see figure 7, section A). In the ESI 
chromatograms for Halecium muricatum (M11046) (see figure 6, B and C) many compounds 
were detected during the first 10 minutes, but compounds were detected until 35 minutes. For 
Halecium beanii (M11047) the ESI chromatograms (figure 7, section B and C) showed that 
the eluted compounds were detected throughout the whole gradient. 
Figure 6: Chromatograms of preparative HPLC of the aqueous extract of Halecium muricatum (M11046). A: 
UV- data measured at 200- 600 nm. B and C: ESI in negative and ESI in positive mode measured at m/z 100 – 
1500. The peaks are annotated with retention time (top) and UV absorbance (bottom) in the UV chromatogram, 




Figure 7: Chromatograms of preparative HPLC of the aqueous extract of Halecium beanii (M11047). A: UV- 
data measured at 200- 600 nm. B and C: ESI in negative and ESI in positive mode measured at m/z 100 – 1500. 
The peaks are annotated with retention time (top) and UV absorbance (bottom) in the UV chromatogram, and 




In the UV chromatogram of the organic extract of Halecium muricatum (M11046) the 
injection peak had the retention time of 2.55 minutes and was dominating (figure 8, section 
A). For Halecium beanii (M11047) the UV chromatogram showed a dominating injection 
peak at 2.53 minutes, and the majority of compounds were detected between 15 and 25 
minutes. In the ESI chromatograms most compounds were detected between 15 and 25 
minutes for both H. muricatum and H. beanii (figure 8 and 9, section B and C). 
Figure 8: Chromatograms of preparative HPLC of the organic extract of Halecium muricatum (M11046). A: 
UV- data measured at 200- 600 nm. B and C: ESI in negative and ESI in positive mode measured at m/z 100 – 
1500. The peaks are annotated with retention time (top) and UV absorbance (bottom) in the UV chromatogram, 






Figure 9: Chromatograms of preparative HPLC of the organic extract of Halecium beanii (M11047). A: UV- 
data measured at 200- 600 nm. B and C: ESI in negative and ESI in positive mode measured at m/z 100 – 1500. 
The peaks are annotated with retention time (top) and UV absorbance (bottom) in the UV chromatogram, and 













6.2 Bioactivity testing 
 
6.2.1 Growth inhibition assay  
 
Growth inhibition assay 1
st
 screening of the aqueous extracts 
 
The first screening of the aqueous extracts of both Halecium muricatum (M11046) and 





Figure 10: First growth inhibition screening of the aqueous extract of Halecium muricatum (M11046) against E. 


































Figure 11: First growth inhibition screening of the aqueous extract of Halecium beanii (M11047) against E. 
faecalis, E. coli, P. aeruginosa, S. aureus and Streptococcus gr. b. 
 
Growth inhibition assay 1
st
 screening of the organic extracts: 
The 1
st
 screening of the organic extracts of Halecium muricatum (M11046) and Halecium 
beanii (M11047) showed many fractions with activity against Streptococcus gr. b (see figure 
12 and 13 below).  
The results from Halecium muricatum (M11046) showed that many fractions only were active 
against one of the five different strains of bacteria, respectively Streptococcus gr. b (see figure 
12). The following fractions showed activity against this bacteria; 20-22 and 26-30.  
The results for Halecium beanii (M11047) showed that fewer fractions had antibacterial 
activity compared to the organic extract of Halecium muricatum (see figure 13). Fraction 27, 
28, 29 and 30 showed activity against Streptococcus gr. b, and fraction 27 also showed 































































 growth inhibition screening of the organic extract from Halecium muricatum (M11046) 





 growth inhibition screening of the organic extract from Halecium beanii (M11047) against E. 






































Growth inhibition assay 2
nd
 screening of active fractions from the organic extracts 
 
The second screening of the active fractions from the organic extracts of Halecium muricatum 
(M11046) and Halecium beanii (M11047) showed that some of the fractions that showed 
activity initially, was not active in the 2
nd
 screening (see figure 14 and 15 below). The purpose 
of the 2
nd
 screening was to confirm the activity from the 1
st
 screening and check for a dose- 
response relationship between the three different dilutions of the fractions. There was no clear 
dose- response relationship established. However, some of the fractions that showed activity 
in the first screening still showed activity undiluted, and  fraction 29 from Halecium beanii 





 growth inhibition screening of the organic extract from Halecium muricatum (M11046) against 




 screening of Halecium muricatum (M11046) four of the initially eight active 
organic fractions showed activity against Streptococcus gr. b in the undiluted form. These 






























 growth inhibition screening of the organic extract from Halecium beanii (M11047) against 




 screening of  Halecium beanii (M11047) against Streptococcus gr. B resulted in two 
active fractions, fractions 29 and 30. Fraction 29 showed activity in the undiluted form, and 





















































Initially fraction 27 from Halecium beanii (M11047) showed weak activity against 
Enterococcus faecalis, and this was retested. The results from the 2
nd
 screening showed that 
this fraction was not active against this bacterium (see figure 16). 
 
6.2.2 Anticancer assay 
 






 screening of the aqueous extract of Halecium muricatum (M11046) against the 
human melanoma cell line, A2058, six fractions showed activity. These fractions were 



































 screening of the aqueous fractions of Halecium beanii (M11047) there was only one 





 anticancer assay of the aqueous extract of Halecium beanii (M11047) against the A2058 cell line. 
 




The active fractions from the 1
st
 anticancer screening were retested undiluted, diluted 1:2 and 
1:5, to investigate if the results were reproducible and to check for a dose- response 
relationship. All of the initially active fractions of Halecium muricatum (M11046) showed 
activity in the undiluted form in the 2
nd
 screening (see figure 19). When diluted 1:2 fraction 3, 
4, 5 and 6 showed activity, whereas fraction 7 and 13 showed weak activity. From figure 19 it 
was obvious that fraction 3 and 4 were the fractions that showed the strongest activity, and 
































 anticancer assay of the initially active fractions from the aqueous extract of Halecium 
muricatum (M11046) against the A2058 cell line. 
 
Fraction 3 from the aqueous extract of Halecium beanii (M11047) showed a high activity in 
all degrees of dilution in the 2
nd





 anticancer assay of the initially active fraction 3 from the aqueous extract of Halecium beanii 





























































 screening of the organic fractions showed numerous fractions with activity against the 
human melanoma, A2058, cell line. The two figures below (21 and 22) show that almost the 
same fractions of Halecium muricatum and Halecium beanii were effective against A2058. 





 anticancer assay of the organic extract of Halecium muricatum (M11046) against the A2058 cell 
line. 
 
For Halecium muriatum (M11046) fractions 16-33 were active, with the exception of fraction 




























 anticancer assay of the organic extract of Halecium beanii (M11047) against the A2058 cell line. 
 
For Halecium beanii (M11047) fractions 18-30 from the organic extract of Halecium beanii 
(M11047) showed activity (see figure 22). 
 




The fractions from the 1
st
 screening that showed activity was retested in the 2
nd
 screening 
undiluted, diluted 1:2 and diluted 1:5. As we can see from figure 23 and 24, the majority of 
the initially active fractions of Halecium muricatum (M11046) and Halecium beanii 
(M11047) were active in the 2
nd






























 screening of the organic extract from Halecium muricatum (M11046) against the human 
melanoma cell line A2085. 
 
The results from the 1
st
 screening of Halecium muricatum (M11046) were highly reproducible 
(see figure 23), since all initially active organic fractions, except fraction 17, showed activity 
against A2058 in the 2
nd
 screening in the undiluted form. All fractions except fraction 16 and 
17 showed activity when diluted 1:2.  When diluted 1:5, fraction 19, 20, 26, 29 and 30 






























 screening of the organic extract from Halecium beanii (M11047) against the human melanoma 




 screening of Halecium beanii (M11047) no clear dose- response relationship was 
established (see figure 24). All fractions showed activity in the undiluted form. Fractions 19, 
20, 22, 27, 28, 29 and 30 showed activity when diluted 1:2. Two fractions showed activity 




The analysis of the organic HPLC fractions from Halecium beanii (M11047) by HR- MS 
showed the presence of many compounds. Eight compounds were present in relatively large 
amounts in the active fractions, compared to the inactive fractions. These compounds had the 
m/z values 452.3, 454.3, 480.3, 482.3, 508.3, 508.3, 510.3 and 512.3 as the protonated 
molecular ions. One example is shown where the active fraction 22 from Halecium beanii 
(M11047) was compared to the inactive fraction 15 from the same organism (see figure 25). 

























the active fraction and not in the inactive fraction. It was therefore likely that one or more of 
these three compounds contributed to the bioactivity observed in fraction 22.  
From the accurate protonated mass of compound 1 (454.3273, see figure 29), the elemental 
composition was calculated to be C22H49NO6P, and from the accurate protonated mass of 
compound 2 (482.3582, see figure 29) the elemental composition was calculated to be 
C24H53NO6P. These protonated masses and the masses to the six other compounds correlated 
with molecular masses of different phosphocholines from searches in the Dictionary of 
Marine Natural Products. Compound 1 correlate with 1- Tetradecylglycero-3-phosphocholine, 
and compound 2 correlate with 1- Hexadecylglycero-3-phosphocholine. 
Figure 25: Chromatogram ESI+ (m/z 150-1500) comparing active fraction 22 (M11047) with the inactive 
























Figure 27: Compound 2, 1- Hexadecylglycero-3-phosphocholine. 
 
6.4 Isolation of possible bioactive compounds from Halecium beanii 
 
After the dereplication of the eight different compounds, the compounds needed to be isolated 
to confirm their structure and bioactivity. In total 412.9 mg of organic extract from Halecium 
beanii (M11047) was used in the isolation process. The gradient used on the HPLC in the 
isolation process was optimized. The starting point for this gradient was from the gradient 
used during fractionation, and was further optimized resulting in chromatograms where the 
different compounds were separated satisfactory, and the fraction collection did not overlap 
(see figure 28). The molecular weights of the eight compounds triggered fraction collection. 
54 
 
Figure 28: Example from the isolation of compounds from the organic extract from Halecium beanii (M11047). 
 
After isolation, the compounds were analyzed with TOF- MS to determine the purity of the 
compounds. Due to time constrains, we could not investigate all eight compounds, and 
therefore we chose to proceed with the two purest compounds.  Compound 1 and compound 2 
were purest (see figure 29), and were chosen for further bioactivity testing. Figure 29 
indicates that compound 1 and 2 were relatively pure. After the isolation and drying process 
the amount available of the two compounds was 0.7 mg for compound 1 and 1.1 mg for 





Figure 29: Compound 1 (bottom) and compound 2 (top) analyzed with MS- TOF in the isolation process. 
 
Figure 30 displays the MS spectra for compound 1 and 2. For compound 1 the peak with the 
protonated mass 454.3 was the molecular ion with an additional hydrogen ([M+H]
+
), the 
protonated mass 455.3 was the isotope of the molecular ion containing one 
13
C, and the peak 
with the protonated mass 456.3 was the isotope of the molecular ion containing two 
13
C. The 
peak with the protonated mass 907.6 was [2M+H]
+
, and the protonated masses 908.6 and 
909.6 were the isotopes of [2M+H]
+
 containing one and two 
13
C.  The mass 1360.7 was 
[3M+H]
+
. The same pattern goes for compound 2, where the protonated mass 482.3 was the 
molecular ion and a proton ([M+H]
+
), mass 483.3 and 484.3 were the protonated molecular 
ion containing one and two 
13
C. The mass 963.7 was [2M+H]
+
, and the masses 964.7 and 
965.7 were [2M+H]
+
 containing one and two 
13







Figure 30: MS specter for compound 1 (bottom) and compound 2 (top). 
 
6.5 Identification of possible bioactive compounds from Halecium beanii 
 
HR- MS 




The spectrum that gave most information was the Wet1D (
1
H- NMR) spectrum (see figure 
31). 1D 1H- NMR is quantitative, which means that the area under each peak is proportional 
to the number of protons giving rise to the resonance. The peaks in this spectrum were 
integrated, by setting one peak as a reference peak. The integrals were normalized on the peak 
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of the identical hydrogen atoms adjacent to the nitrogen atom peak, corresponding to nine 
protons. They have the intensity of nine hydrogen atoms. When compared with the hydrogen 
atoms on the methyl- tail to the ω- carbon the ratio should be 9:3, if this sample was pure. 
However, the ratio was 6:3. This implies that there was a mixture of different 
phosphocholines in the sample. A ratio of 6:3 could mean two things. One, that the sample 
contained a mixture of different phosphocholines that had one and two tails. Two, that the 
sample contained a mixture of different phosphocholine- like compounds without the NC3- 
group. Both of these possibilities would shift the ratio from 9:3 to 6:3. The gHSQCAD, 
gHMBCAD and gCOSY spectra did not give any additional information, other than the head 
group was consistent with a choline, but the resonances of the tail(s) were severely crowded 
preventing explicit assignment. At this point, there was no evidence which states that the 
compound in question was not 1- Tetradecylglycero-3-phosphocholine. It was certain 
however that the sample contains a mixture of different phosphocholines. To further identify 
the phosphocholines present, and confirm or disprove that this mixture contains 1- 






















Again the spectrum that gave most information was the Wet1D (
1
H- NMR) spectrum (see 
figure 33).  The peaks in this spectrum were integrated, by setting one peak as a reference 
peak. In this case the reference peak was the hydrogen atom on the E carbon. If this sample 
was pure, the ratio between the hydrogen atom on the E- carbon and the hydrogen atoms on 
the ω- carbon would be 1:3. Instead the ratio was 1: 7.5. This again implies that there was a 
mixture of phosphocholines in the sample. A source of error occurs when a peak consisting of 
one hydrogen atom is used as the reference peak, so the ratio of 1:7.5 really might be 1:6 (see 
section 7 for further discussion about sources of error). That implies that in this sample, there 
were phosphocholines with two tails. Another possibility was one tail, but with a different 
head group or some other difference near E, and this could also shift the ratio between E and 
the tail. Another example that supports this was the intensity of the integrated peak of the 
hydrogen atoms on the γ- carbons. If this sample only contained 1- Hexadecylglycero-3-
phosphocholine the ratio would be 1:24. Instead the ratio is 1:51. This supports the theory that 
there was a mixture of different phosphocholines, with different numbers of tails. When the 
ratio between the hydrogen atom on the E- carbon and the hydrogen atoms on the NC3- group 
were compared the ratio was 1:6.5. As with the other sample, this could imply that in this 
mixture, there was some phosphocholine- like compounds which lack the NC3- group.  
Information from the gHSQCAD+ gHMBCAD spectra implies the presence of a carbonyl- 
group on the α- carbon. However, it was difficult to say for sure if it was on the same 
molecule, an overlapping impurity or something in the sample mixture. It may not be the main 
component. When these results are added up, the conclusion was that there was a mixture of 
phosphocholines in the sample. To confirm or disprove the presence of 1- Hexadecylglycero-










Figure 33: Wet1D specter for compound 2. 
Figure 34: 
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From the MS-MS spectrum below of compound 1 (see figure 36), three relatively large peaks 
in addition to the protonated molecular ion 454 ([M+H]
+
) were observed. The three fragments 
were 86, 104 and 184. There was a small peak at m/z 437 indicating a loss of a hydroxyl 
group, since the m/z difference between 454 and 437 was 17.  
 
Figure 36: MS-MS spectrum of compound 1. 
 
Compound 2: 
For compound 2 the three first fragments in the spectrum were the same fragments found in 
the spectrum for compound 1. In addition to two other fragments, and the protonated 
molecular ion 482 ([M+H]
+




Figure 37: MS- MS spectrum of compound 2. 
 






Figure 38: Proposed mass fragmentation from phosphocholines. Top left: m/z 86, top right: m/z 184, and on the 






These fragments were fragments from the phosphocholine head group. The fragment with m/z 
278 was difficult to interpret. However this fragment only appeared in one scan, and was 
therefore most likely an artifact, not a fragment from compound 2 (see figure 39).   
 
 
Figure 39: Data from the MS-MS scan, showing the real fragment with m/z 184 (top), one scan detecting the 
artifact with m/z 278.78 (middle) and TIC (bottom). 
 
Figure 39 also displays that the fragment with m/z 184 occur throughout the whole analysis 
and with higher intensity when the TIC intensity was increased.  
The peak with m/z 465 was compound 2 after the loss of a hydroxyl group, since the mass 







6.6 Confirmation of bioactivity 
 
As stated earlier the confirmation of bioactivity was necessary, since the compounds isolated 
might not be the compounds responsible for bioactivity or the bioactivity can be the result of a 
synergic effect from multiple compounds. In the case of compound 1, there were no 
concentrations that were defined as active, according to the preset values, against either cell 
line (see figure 40 below). There was not activity against the A2058 (human melanoma) cell 
line at the concentrations tested (2.5 – 100 µg/ mL), which the active fractions showed 




 screening. It is therefore highly likely that the compound 
was not the compound responsible for bioactivity, or was part of a synergic effect. Against the 
cell line MRC5 compound 1 showed a weak effect at 100 µg/ mL (74 % cell survival). 
 
 
























Concentration of compound 








Figure 41: Result from bioactivity testing of compound 2 against four cell lines with standard deviations from 
three parallels.  
 
Compound 2 showed activity against all the cell lines, except the DU145 cell line at 100 µg/ 
mL (see figure 41). Against the cell lines A2058 and MRC5 the compound showed good 
activity at the two highest concentrations, 75 µg/ mL and 100 µg/ mL respectively. Against 
MCF7 (human breast carcinoma) the highest concentration of compound 2 showed weak 
activity (57 % cell survival). Compound 2 showed a dose- response relationship against the 
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New anticancer agents are needed for many reasons. Today the treatment is accompanied by 
many side effects, and one wish to increase the rate of survival. At the same time the 
population of the western world gets older and the cancer incidence is increasing. There is 
also a need for new antibiotics with novel mechanisms of action because of the development 
of bacterial resistance. To battle this development of resistance the funding of R & D needs to 
be increased, yet the pharmaceutical companies decrease their funding.  The marine 
environment is underexplored and has an unparalleled biodiversity, which is one reason for 
establishing new centers in the field of marine bioprospecting. Academics are establishing 
new centers, but the pharmaceutical industry is still on the sideline, despite the previous 
discoveries and the potential in marine bioprospecting.   
The aim of this work was to isolate and characterize the structure of bioactive compounds 





 screening against human cancer cell lines and different bacterial strains, both 
organisms had many bioactive fractions, especially fractions from the organic extract. To our 
best knowledge there is no work about Halecium muricatum and Halecium beanii and their 
bioactivities, only literature about the identification of hydroids.  
Extraction was obviously an important step to produce extracts that can be used for 
bioactivity assays. The method used for extraction was a specific protocol utilized by the 
National Cancer Institute (NCI) to preserve the biologically active molecules the biomass 
sample contain. The aqueous extraction was carried out first since this extraction was quicker 
than the organic extraction, which minimizes the time the sample was not frozen. This 
timeframe was very important, since marine samples deteriorate rapidly when not frozen. The 
maximum time the sample can be out of the freezer is two hours [38]. The weight of the 
aqueous extract typically exceeds by far the weight of the organic extract. The reasons for this 
high yield for the aqueous extract is the presence of high molecular weight compounds like 
polysulfated polysaccharides, peptides, proteins and the sea salt from the sea water. The 
extraction yield for the organic extract is typically 3-5 % after using DCM and MeOH, thus 
the yield from Halecium muricatum (M11046) and Halecium beanii was normal. However, 
the yield would be higher if the organic extraction was carried out first, but this increase in 
yield would be associated with the increased amount of sea salts and other substances in the 
organic extract, since they are partly soluble in MeOH. Therefore when doing the aqueous 
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extraction before the organic extraction, the constituents in the organic extract are dominated 
by smaller, moderately polar and non- polar compounds, which are the compounds most 
likely to exhibit drug- like properties. Performing the aqueous extraction before the organic 
extraction minimize the amount of salts present in the organic extract, which leads to a higher 
concentration of compounds with possible drug- like properties in the micro titer plate when 
conducting bioactivity assays. This because the amount of salts would comprise a large part of 
the approximately 200 mg of organic extract used in the bioactivity assays. A higher 
concentration makes it more likely to detect the bioactivity in the organic extract [38].    
Before the bioactivity assays, the organic and aqueous extracts from the two organisms 
needed to be fractionated. The fractionation was satisfactory, based on the fact that it was 
possible to distinguish between compounds present in inactive and active fractions (see figure 
25). This also indicated that the gradient developed for use in the fractionation was working 
as intended. The UV chromatograms, perhaps with the exception of the chromatogram of the 
organic extract of Halecium beanii (M11047), did not give much information, because of the 
few signals detected. The compounds that often show bioactivity are eluted in the middle of 
the gradient used in the fractionation of organic extracts. The reason for this is that these 
compounds are not too polar or not to lipophilic. If the compound is too hydrophilic or 
hydrophobic it would not be able to cross membranes, and if it is too lipophilic it would 
precipitate in the blood. Therefore a trait of an effective drug is a balanced lipophilic/ 
hydrophilic character.  
In this work the aqueous and organic extracts go through bioactivity assays before isolation, 
instead of isolation of the compounds from the extracts without the support of bioactivity 
assays. The disadvantage for the latter course of action is the fact that isolation is a time 
consuming process, and when the results from these bioactivity assays are available there is a 
possibility that the compounds tested show no sign of bioactivity. With the course of action in 
this work, results from bioactivity assays are available at an early stage, which support the use 
of resources for further isolation and structure elucidation. However there are disadvantages 
to go through with bioactivity assays before isolation as well. The one minute fractions that 
undergo bioactivity assays contain many compounds, and the possibility of a synergic effect 




The bioactivity assays done in this work were against cancer and bacteria, with anticancer 
assays as the main focus. After the 1
st
 screening it was obvious that the number of active 
organic fractions exceeded by far the number of active aqueous fractions. Few fractions from 
the aqueous extracts showed bioactivity against the cell line A2058 in the 1
st
 screening, and 
no fractions showed bioactivity against the different strains of bacteria. Many organic 
fractions showed bioactivity in the 1
st
 screening against the A2058 cell line, and a couple of 
fractions showed good activity against Streptococcus group B in the growth inhibition assay. 
Fraction 27 from the organic extract of Halecium beanii (M11047) also showed weak activity 
against E. faecalis and S. aureus, but in the 2
nd
 screening the result for E. faecalis was not 
reproducible. Because of the limited timeframe and since cancer was the main focus, the 2
nd
 
screening of S. aureus was not performed. The reason for the 2
nd
 screening, after the 1
st
 
screening, was to confirm the bioactivity found in the 1
st
 screening and check for a dose- 
response relationship. In the 2
nd
 screening of the aqueous extracts against cell line A2058, 
fraction 3 and 4 from Halecium muricatum (M11046) and fraction 3 from Halecium beanii 
(M11047) showed activity. This was expected, since fraction 3 from the aqueous extracts 
often shows activity. The reason for this may be that sea salt, polysulfated polysaccharides, 
peptides and proteins elute in high concentrations in this fraction, leading to an extremely 
unsuitable environment for cells to survive. In the 2
nd
 screening of the organic extracts many 
fractions showed activity, even in the most diluted form. All fractions from Halecium 
muricatum (M11046) except fraction 17 showed activity in the undiluted form, indicating that 
the results were reproducible. Fractions 19, 20 and 26 showed good activity in the undiluted 
and diluted forms. All fractions from Halecium beanii (M11047) in the 2
nd
 screening showed 
activity in the undiluted form, seven fractions showed activity when diluted 1:2. Fraction 22 
and 29 showed activity over the grades of dilution.  Halecium muricatum (M11046) had a 
larger number of active fractions compared with Halecium beanii (M11047), but nearly the 
same fractions showed activity in the anticancer assay and in the growth inhibition assay. This 
indicated that it might be the same compounds responsible for the observed bioactivity, and 
the results from the fractionation support this because many of the isolated compounds from 
Halecium beanii (M11047) were found in Halecium muricatum (M11046) as well. Halecium 
muricatum and Halecium beanii are closely related species so this was not surprising.  
The organic extract from Halecium beanii (M11047) was chosen for dereplication because of 
the amount of sample available for further testing and the observed bioactivity. The amount of 
sample available was the double of that available for Halecium muricatum (M11046) (see 
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section 6.1.1). Both organic extracts from the two species showed many fractions with strong 
bioactivity in the anticancer screening. Thus, according to a bioactivity point of view, both 
Halecium muricatum (M11046) and Halecium beanii (M11047) were very similar. However, 
the number of active fractions after the 2
nd
 screening obviously was in favor of Halecium 
muricatum (M11046), but that does not make up for the amount of sample available, which 
clearly was in favor of Halecium beanii (M11047).  
In bioprospecting the amount of sample available is a common problem, and is the reason for 
cultivating marine bacteria which gives a reliable resupply of samples. It is more difficult to 
cultivate marine invertebrates, and are therefore dependent on that an adequate amount of 
samples are collected to perform all tests. However, it was likely that the same compounds are 
responsible for the bioactivity observed, so the obvious choice was to choose Halecium beanii 
(M11047) for dereplication.  
After the isolation of the eight compounds, compound 1 and 2 were purest. However, more of 
compound 1 and 2 were required for confirmation of bioactivity and structure elucidation. An 
optimized isolation gradient was used to isolate the two compounds from the organic extract 
from Halecium beanii (M11047). This optimized gradient was found by trial and error, and 
ensured a satisfactory separation of the eight compounds.  
The accurate masses of compound 1 and 2 were used with the isotope patterns to calculate 
molecular formulas for these compounds. These molecular formulas were used to search the 
Dictionary of Marine Natural Products for known compounds. At this point it was believed 
that the two compounds were two different phosphocholines, but further structure elucidation 
was needed to confirm this. NMR was utilized first to check the relationship between the 
hydrogen and carbon atoms, but from the NMR data it was evident that the samples were less 
pure than expected. From the different integrals from 
1
H- NMR and 
13
C- NMR it was obvious 
that in these samples there was a mixture of other compounds, perhaps different 
phosphocholines, where some had two tails and others one tail. This made it impossible to 
rely on the NMR data alone. The optimized gradient from the isolation process could have 
been further improved, and the result would have been more pure compounds. However, 
optimizing a gradient is time consuming, and the extended manipulation of samples could 
give a lower yield.  
There were several potential sources of error using a single proton as a reference peak. If a 
single- proton used as a reference measured a three proton resonance, it gives three times the 
71 
 
error on the 3- peak, and six times the error on the 6- peak. Another source of error is 
overlapping peaks. If there is something hidden under the peak that will add up with the peak 
of interest, the peak of interest will look bigger than it actually is. The third source of error is 
the different relaxation properties of different protons which can affect their signal as well. 
This did not concern 
1
H- NMR in the same degree as 
13
C-NMR, which was not quantitative 
because of the way it was acquired. 
From the MS- MS spectra of compound 1 and 2 it was obvious from the fragments from the 
phosphocholine head- group with m/z 86, 104 and 184 that these two compounds were 
phosphocholines. These fragments are typical fragments when analyzing MS- MS data from 
phosphocholines. However, the aliphatic part of the molecules was impossible to determine 
from the MS-MS spectra. It was fairly certain that compound 1 and 2 were present in the two 
samples, but it could be a mixture of different phosphocholines in the samples as well. From 
these results it could have been advantageous to have isolated the two compounds further and 
worked more with the isolation gradient. However, further isolation could have led to a lower 
yield and a shortage of sample for further bioactivity assays and analysis.  If the structure 
elucidation was to be taken further GC- MS with electron ionization would be the next step. 
With GC- MS with electron ionization the bonds between the carbons in the aliphatic part of 
the molecule would break, and the fragments would appear in the spectrum. Possible side 
chains in the aliphatic moiety would be detected, and the molecule could be identified. 
When the isolated compounds were tested against the different cell lines, compound 1 showed 
weak activity against the MRC5 cell line, and no activity against the DU145, MCF7 and 
A2058 cell lines. The organic fractions from Halecium beanii (M11047) showed activity 




 screening, so the explanation of the results may 
be that compound 1 was not responsible of the observed bioactivity or synergy between 
multiple compounds in the organic extract.  
Compound 2 showed weak activity against the MCF7 cell line and good activity against the 
cell lines MRC5 and A2058 in higher concentrations. However, it was not desirable that 
compounds show activity against the MRC5 cell line, since this cell line consisted of normal 
lung fibroblasts, and was a toxicity control.  The observed strong activity against this cell line 
was an indication of general cytotoxicity which obviously was undesirable, since this effect 
would lead to serious side- effects if used clinically.  
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Literature about phosphocholines, especially alkylphosphocholines and their synthetic analogs 
are previously published. In these works a wide spectrum of activity has been connected with 
these compounds and especially hexadecylphoshocholine, namely antineoplastic, 
antibacterial, antimycotic, antiprotozoal and antiviral activities [39]. There is also a registered 
drug, miltefosine (see figure 42), a synthetic analog of hexadecylphosphocholine, which is 
used clinically against visceral and cutaneous leishmaniasis and in clinical studies miltefosine 
showed promising results against cutaneous metastases of mammary carcinomas when 
administered topically [40]. One work proposed that alkylphosphocholines’ and other 
synthetic anti- tumor lipids (ATLs) main site of action is at the plasma membrane and 
interferes with cellular phospholipid metabolism. It was also proposed that ATLs alter the 
fluidity of cell membranes and lead to membrane pore formation which permeabilised cells 
[41]. Newer work indicates that miltefosine lead to an increased cholesterol uptake, synthesis 
and accumulation of cholesterol inside the cell. This is achieved by impairing the transport of 
cholesterol into the endoplasmic reticulum (ER), but not the transport of cholesterol from the 
ER. It is also indicated that phosphatidylcholine and sphingomyelin synthesis was reduced by 
miltefosine, and these effects together affected the membrane stability and function, which 
can inhibit tumor cell growth, and can induce apoptosis [40]. However the main mechanism 
of action remains unclear, but it is a possibility that there are multiple events acting in concert 
to inhibit tumor cell growth. It was also proposed that the different effects are dose- 
dependent [41].  The work that indicated that alkylphosphocholines have their main site of 
action at the plasma membrane fits with the observed activity of compound 2. Compound 2 
showed no cancer cell specificity, which indicated a general cytotoxicity, probably by 
affecting the cell membrane leading to cell death. The observation that some fractions from 
the organic extract of Halecium beanii (M11047) also exerted antibacterial activity indicated 
that there was a general cytotoxic effect which did not differentiate between eukaryotic and 
prokaryotic cells. 
  




The accurate masses of the eight compounds found after the dereplication fits for different 
phosphocholines, but without NMR and MS- MS data their exact structures were uncertain. 
These compounds could have been tested for bioactivity, to see if they had a more specific 
activity than compounds 1 and 2. Before this bioactivity testing, they could have been 
analyzed by MS- MS to see if they had the recognizable fragments with m/z 86, 104 and 184 
which indicates phosphocholines. If they had these fragments, further bioactivity testing 
would give additional information about possible selectivity differences. Synthetic 
phosphocholines like the alkyl phosphocholines show a broad spectrum of bioactivity and the 
phosphocholine head group (main group) could be used as a scaffold for combinatorial 
chemistry. This could make their effect more selective, and structure activity relationships 
(SAR) could be used as well to optimize the selectivity and bioactivity against different 
bioactivity assays. However there is one drawback. One alkyl phosphocholine is a registered 
drug, miltefosine as mentioned above. The pharmaceutical company who own the rights have 
most assuredly taken out patents for a vast array of similar compounds, which limits the 
probability of making new discoveries. Before a potential synthesis of a synthetic 
phosphocholine, information about which compounds that is protected by patents are 
necessary, to limit wasting of resources.  
The probability of finding previously known compounds are increasing since bioprospecting 
has been done for quite some time. Therefore new methods for detecting known compounds 











8. Conclusion and further perspectives 
 
The organic extracts from Halecium muricatum (M11046) and Halecium beanii (M11047) 




 screening against the A2058 cell line and Streptococcus 
group B. Several compounds were isolated from the active fractions, and based on purity two 
compounds (compound 1 and 2 from Halecium beanii) were selected for further activity 
testing and structure elucidation. Compound 1 showed weak activity against MRC5 at the 
highest concentration, whereas compound 2 showed a weak effect against MCF7 and good 
effect against MRC5 and A2058 at 100 µg/ mL. Activity against MRC5 which was normal 
lung fibroblasts was undesirable since this cell line was used as a toxicity control. The 
aqueous extracts did not show any activity against the different strains of bacteria, but some 
fractions showed good activity against the A2058 cell line. The structure elucidation led to the 
confirmation that compound 1 and 2 were phosphocholines, however the exact structures 
were not confirmed.  
Phosphocholines are interesting compounds responsible for a wide range of bioactivities, for 
example versus bacteria, cancer and viruses. It is thought that phosphocholines exert their 
activity on the cell membrane, or that cell death is a result of apoptosis. In future studies the 
other six of the eight compounds from the dereplication could be tested for their bioactivity 
against cancer to check for specificity against cancer cell lines. Further structure elucidation 
utilizing GC- MS with electron ionization for determination of possible side chains in 
compound 2 could be done as well, followed by synthesis of synthetic phosphocholines. 
Different side chains and length of the side chains of the synthetic phosphocholines could be 
tested for their bioactivity, to detect a potential selectivity for cancer cell lines. However 
patented phosphocholines needs to be checked, to know which compounds are patented. 
Optimization of side chains may lead to selectivity against cancer cell lines and higher 
potency, while the toxicity is minimized.  
The results of this work can change the methods used by MabCent for bioactivity testing. MS- 
MS data of the organic extract would give the previous mentioned recognizable fragments 
from phosphocholines at an earlier stage, before bioactivity assays. If there is a patent on a 
phosphocholine against the target used in the assay, there is no point in doing the assay, 
because a potential hit would not lead to a new discovery. This work has therefore contributed 
to shorten the time before detecting the presence of phosphocholines in the sample. To the 
best of our knowledge, there is no work about the bioactivity of hydroids published. Therefore 
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this work may be the first to describe the bioactivity of the hydroids Halecium muricatum and 
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